LIST OF TABLES

Table No.	Title	Page No.
2.1.	Endogenous angiogenic and anti-angiogenic factors	11
2.2.	Neuropilins and VEGFRs expression in tumor cells	20
2.3.	Components of immunoliposomes design	23
2.4.	Examples of active targeted liposomes under preclinical and clinical trials	27
2.5.	Conjugation strategies of active targeted liposomes under preclinical and clinical trials	28
2.6.	Analytical methods for docetaxel	33
3.1.	UV calibration curve values of docetaxel in methanol at λ_{max} of 231nm	49
3.2.	RP-HPLC calibration curve values of docetaxel in methanol at λ_{max} of 231nm	51
3.3.	RP-HPLC calibration curve values of 7-epidocetaxel in methanol at λ_{max} of 231nm	53
3.4.	RP-HPLC calibration curve values of 10-oxo-7-epidocetaxel in methanol at λ_{max} of 231nm	54
3.5.	Comparison of HPLC data of docetaxel and its impurities	55
3.6.	Calibration curve values of phospholipid mixture in chloroform at λ_{max} of 472nm	56
3.7.	Calibration curve values of BSA at λ_{max} of 562nm	57
3.8.	Calibration curve values of BSA at λ_{max} of 595nm	58
3.9.	Calibration curve values of cysteine at λ_{max} of 412nm	60
4.1.	Independent variables and their corresponding levels	71
4.2.	3^3 full factorial design consisting of experiments for the study of 3 experimental factors in coded and actual levels with experimental results	72
4.3.	Effect of some process parameters on % drug loading and mean particle size of optimized formulation AL-11	73
4.4.	Effect of cholesterol concentration on % drug loading and mean particle size	74
4.5.	Comparison of % docetaxel and impurities loading after preparation of liposomes at different hydration temperature in the absence of organic acid	77
4.6.	3^3 full factorial design consisting of experiments for the study of 3 experimental factors in actual levels with experimental results	78
4.6a.	2*3 factorial design to study the influence of the 3 experimental factors (X1, X2, X3) in coded levels on % drug loaded (Y_2) in liposomal batches	79
4.7.	Comparison of vitamin-E and organic acids as degradation inhibitors	82

5.1.	Effect of DSPE-mPEG$_{2000}$ concentration on % drug content and mean particle size	92
5.2.	Comparison of PEGylated liposomes (5 mol%) composed of HSPC and DPPC both and HSPC and DPPC individually	93
5.3.	Influence of sodium sulfate concentration on absorbance of the liposomal preparation.	94
5.4.	Influence of sodium sulphate concentration on mean particle size of liposomes	95
5.5.	The % liposomes recovered after separation through Sepharose CL 4B column	97
5.6.	Mean particle size and zeta potential of anionic liposomes before and after incubation with foetal bovine serum	98
5.7.	The amount of serum proteins associated with recovered anionic liposomes	99
5.8.	Estimated cysteine (thiol) concentrations using Ellman's assay	103
6.1.	Comparison of PEGylated liposomes and immunoliposomes	122
6.2.	Comparison of % RMFI of A549 cells treated with different concentrations of Fab fragments and immunoliposomes to determine their immunoreactivity towards neuropilin-1 receptors	127
7.1.	Neuropilins and VEGFRs expression in tumor cells	132
7.2.	Comparison of resolving gel	134
7.3.	Comparison of stacking gel	135
7.4.	Sample loading buffer composition	135
8.1.	Cumulative % DTX released from different formulations	155
8.2.	Comparison of % cumulative DTX released from PLs and PILs with Taxotere	156
8.3.	Formation of docetaxel impurities in release medium of different formulations	157
8.4.	Comparison of *in vitro* stability of PLs in the presence and absence of 10% sucrose	160
8.5.	The comparison of the IC_{50} values (nM) of TXT, CLs, PLs, and ILs against A549 and B16F10 cells at different time points	165
8.6.	The % relative mean fluorescence Intensity (RMFI) of A549, B16F10 and K9 cells treated with different concentration of coumarin loaded CLs, PLs, and ILs for different time periods	168
8.7.	The % of A549 cells in G0-G1, S and G2-M phase after treatment with 2nM solution of Taxotere, PLs and PILs for a period of 24hr and 48hr	185
8.8.	The % of B16F10 cells in G0-G1, S and G2-M phase after treatment with 2nM solution of Taxotere, PLs and PILs for a period of 24hr and 48hr	186
9.1.	Tumor volumes of control and formulation treated groups measured during the experiment	196
9.2.	Control and formulation treated group mice body weight measured during the experiment	197

10.1.	The comparison of the IC_{50} values (nM) of Taxotere, 7-epidocetaxel and 10-Oxo-7-epidocetaxel against A549 and B16F10 cells at different time points	217
10.2.	The % A549 and B16F10 cell apoptosis after treatment with 1mL of 2nM, 10nM, and 25nM of Taxotere, 7-epidocetaxel, and 10-oxo-7-epidocetaxel for a period of 24hr and 48hr	225
10.3a.	The % of A549 cells in G0-G1, S and G2-M phase after treatment with 2nM solution of Taxotere, 7-epidocetaxel and 10-oxo-7-epidocetaxel for a period of 24hr and 48hr	235
10.3b.	The % of A549 cells in G0-G1, S and G2-M phase after treatment with 10nM solution of Taxotere (TXT), 7-epidocetaxel (7EDTX) and 10-oxo-7-epidocetaxel (10-oxo) for a period of 24hr and 48hr	236
10.3c.	The % of A549 cells in G0-G1, S and G2-M phase after treatment with 25nM solution of Taxotere, 7-epidocetaxel and 10-oxo-7-epidocetaxel for a period of 24hr and 48hr	237
10.4a.	The % of B16F10 cells in G0-G1, S and G2-M phase after treatment with 2nM solution of Taxotere, 7-epidocetaxel and 10-oxo-7-epidocetaxel for a period of 24hr and 48hr	238
10.4b.	The % of B16F10 cells in G0-G1, S and G2-M phase after treatment with 10nM solution of Taxotere, 7-epidocetaxel and 10-oxo-7-epidocetaxel for a period of 24hr and 48hr	239
10.4c.	The % of B16F10 cells in G0-G1, S and G2-M phase after treatment with 25nM solution of Taxotere, 7-epidocetaxel and 10-oxo-7-epidocetaxel for a period of 24hr and 48hr	240
10.5.	The % group weights after administration of Taxotere alone and Taxotere with 10% impurities separately	243
10.6.	The % group weights following administration of 20mg/kg single dose of 10-oxo-7-epidocetaxel to mice bearing B16F10 pulmonary metastasis	246